Monthly
US$200
Billed every month
Peramivir Injection(帕拉米韦注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 1 applicationAccepted: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders39View records ↓
Under-review filings7View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers42View records ↓
API companies with A status12View records ↓
Chemical-drug catalogue
Loaded records: 39 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 39 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 广州一品红制药有限公司 | 成都百裕制药股份有限公司 | 国药准字H20266260 | 2026/10/13 | 15ml：0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 嘉亨（珠海横琴）医药科技有限公司 | 广东星昊药业有限公司 | 国药准字H20264902 | 2026/06/23 | 15ml：0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江康吉尔药业有限公司 | 浙江康吉尔药业有限公司 | 国药准字H20255783 | 2025/10/21 | 60ml：0.3g（以C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南先施药业有限公司 | 湖南科伦制药有限公司 | 国药准字H20258166 | 2025/08/22 | 15ml∶0.15g （按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诚意药业股份有限公司 | 浙江诚意药业股份有限公司 | 国药准字H20255068 | 2025/07/30 | 15ml∶0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河南润弘制药股份有限公司 | 河南润弘制药股份有限公司 | 国药准字H20254354 | 2025/05/27 | 15ml:0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药银湖制药有限公司 | 石药银湖制药有限公司 | 国药准字H20253945 | 2025/04/15 | 60ml∶0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20253769 | 2025/04/01 | 60ml：0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海华源安徽锦辉制药有限公司 | 上海华源安徽锦辉制药有限公司 | 国药准字H20253603 | 2025/03/11 | 60ml：0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 长春澜江医药科技有限公司 | 山东新时代药业有限公司 | 国药准字H20253095 | 2025/01/08 | 15ml:0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山西阳和医药技术有限公司 | 山西国润制药有限公司 | 国药准字H20249584 | 2024/12/01 | 15ml:0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖北民康药业集团有限公司 | 湖北美林药业有限公司 | 国药准字H20249474 | 2024/12/01 | 15ml:0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南海灵化学制药有限公司 | 海南爱科制药有限公司 | 国药准字H20249386 | 2024/11/15 | 60ml：0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 陕西博森生物制药股份集团有限公司 | 陕西博森生物制药股份集团有限公司 | 国药准字H20249216 | 2024/10/29 | 15ml：0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中国大冢制药有限公司 | 中国大冢制药有限公司 | 国药准字H20244971 | 2024/09/26 | 60ml∶0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽长江药业有限公司 | 安徽长江药业有限公司 | 国药准字H20244617 | 2024/08/05 | 20ml∶0.2g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 武汉人福利康药业有限公司 | 武汉人福利康药业有限公司 | 国药准字H20244196 | 2024/06/28 | 15ml：0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 武汉人福利康药业有限公司 | 宜昌三峡制药有限公司 | 国药准字H20244197 | 2024/06/28 | 60ml：0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南慧泽生物医药科技有限公司 | 湖南科伦制药有限公司 | 国药准字H20244150 | 2024/06/25 | 60ml∶0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 朗天药业（湖北）有限公司 | 朗天药业（湖北）有限公司 | 国药准字H20244152 | 2024/06/25 | 15ml：0.15g（按C15H28N4O4 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 西安京西双鹤药业有限公司 | 西安京双鹤药有限公司 | 国药准字H20244153 | 2024/06/25 | 60ml∶0.3g（按C15H28N4O4 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新华制药股份有限公司 | 浙江国镜药业有限公司 | 国药准字H20244037 | 2024/06/18 | 60ml：0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏吴中医药集团有限公司苏州制药厂 | 湖南科伦制药有限公司 | 国药准字H20243910 | 2024/06/04 | 60ml∶0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福安药业集团烟台只楚药业有限公司 | 福安药业集团烟台只楚药业有限公司 | 国药准字H20243908 | 2024/06/04 | 20ml∶0.2g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 温州海鹤药业有限公司 | 浙江医药股份有限公司新昌制药厂 | 国药准字H20243853 | 2024/05/28 | 60ml：0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 青海晨菲制药有限公司 | 青海晨菲制药有限公司 | 国药准字H20243854 | 2024/05/28 | 15ml：0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川美大康华康药业有限公司 | 四川美大康华康药业有限公司 | 国药准字H20243856 | 2024/05/28 | 15ml：0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 国药集团容生制药有限公司 | 国药集团容生制药有限公司 | 国药准字H20243671 | 2024/05/08 | 15ml：0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团中诺药业（石家庄）有限公司 | 石药集团中诺药业（石家庄）有限公司 | 国药准字H20243670 | 2024/05/08 | 15ml:0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 国药集团容生制药有限公司 | 国药集团容生制药有限公司 | 国药准字H20243672 | 2024/05/08 | 20ml：0.2g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北天成药业股份有限公司 | 河北天成药业股份有限公司 | 国药准字H20243585 | 2024/04/24 | 15ml：0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北天成药业股份有限公司 | 河北天成药业股份有限公司 | 国药准字H20243586 | 2024/04/24 | 60ml：0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏吴中医药集团有限公司苏州制药厂 | 江苏吴中医药集团有限公司苏州制药厂 | 国药准字H20243215 | 2024/02/23 | 15ml∶0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南葫芦娃药业集团股份有限公司 | 海南葫芦娃药业集团股份有限公司 | 国药准字H20243230 | 2024/02/23 | 20ml：0.2g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州爱美津制药有限公司 | 江苏迪赛诺制药有限公司 | 国药准字H20243128 | 2024/01/30 | 15ml:150mg（以C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南通用三洋药业有限公司 | 海南合瑞制药股份有限公司 | 国药准字H20243076 | 2024/01/23 | 15ml:0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 吉林四环制药有限公司 | 吉林四环制药有限公司 | 国药准字H20234725 | 2023/12/29 | 20ml：0.2g（以C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州绿十字制药股份有限公司 | 广州绿十字制药股份有限公司 | 国药准字H20234693 | 2023/12/26 | 60ml∶0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 扬子江药业集团有限公司 | 扬子江药业集团有限公司 | 国药准字H20233886 | 2023/06/30 | 60ml：0.3g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 齐鲁制药（海南）有限公司 | 齐鲁制药（海南）有限公司 | 国药准字H20233789 | 2023/06/27 | 15ml:150mg（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都百裕制药股份有限公司 | 成都百裕制药股份有限公司 | 国药准字H20233678 | 2023/06/07 | 15ml：0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南先施药业有限公司 | 广东星昊药业有限公司 | 国药准字H20233672 | 2023/06/07 | 20ml∶0.2g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 扬子江药业集团四川海蓉药业有限公司 | 扬子江药业集团四川海蓉药业有限公司 | 国药准字H20233617 | 2023/05/29 | 15ml：150mg（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东中润药物研发有限公司 | 广东星昊药业有限公司 | 国药准字H20233372 | 2023/03/24 | 15ml：0.15g（按C15H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 42 distinct approval numbers and 36 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 广州绿十字制药股份有限公司 | 国药准字H20234693 | 60ml∶0.3g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010100475 | NHSA |
| 中国大冢制药有限公司 | 国药准字H20244971 | 60ml∶0.3g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010100967 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20243128 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010101495 | NHSA |
| 江苏吴中医药集团有限公司苏州制药厂 | 国药准字H20243215 | 15ml:0.15g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002010101504 | NHSA |
| 扬子江药业集团有限公司 | 国药准字H20233886 | 60ml:0.3g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010101749 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H20243856 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010102087 | NHSA |
| 扬子江药业集团四川海蓉药业有限公司 | 国药准字H20233617 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010102313 | NHSA |
| 陕西博森生物制药股份集团有限公司 | 国药准字H20249216 | 15ml:0.15g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002010102357 | NHSA |
| 西安京西双鹤药业有限公司 | 国药准字H20244153 | 60ml∶0.3g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010102492 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243586 | 60ml:0.3g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010102662 | NHSA |
| 石药集团中诺药业(石家庄)有限公司 | 国药准字H20243670 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010102777 | NHSA |
| 石药银湖制药有限公司 | 国药准字H20253945 | 60ml∶0.3g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010102964 | NHSA |
| 国药集团容生制药有限公司 | 国药准字H20243671 | 15ml:0.15g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010103205 | NHSA |
| 河南润弘制药股份有限公司 | 国药准字H20254354 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010103257 | NHSA |
| 吉林四环制药有限公司 | 国药准字H20234725 | 20ml:0.2g(以C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010103492 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20253769 | 60ml:0.3g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010104145 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20244037 | 60ml:0.3g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010104187 | NHSA |
| 福安药业集团烟台只楚药业有限公司 | 国药准字H20243908 | 20ml∶0.2g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010104251 | NHSA |
| 浙江医药股份有限公司新昌制药厂 | 国药准字H20243853 | 60ml:0.3g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010104586 | NHSA |
| 浙江诚意药业股份有限公司 | 国药准字H20255068 | 15ml∶0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010104615 | NHSA |
| 浙江康吉尔药业有限公司 | 国药准字H20255783 | 60ml ∶0.3g(以C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010104745 | NHSA |
| 海南海灵化学制药有限公司 | 国药准字H20249386 | 60ml:0.3g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010105775 | NHSA |
| 海南葫芦娃药业集团股份有限公司 | 国药准字H20243230 | 20ml:0.2g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010105789 | NHSA |
| 海南通用三洋药业有限公司 | 国药准字H20243076 | 15ml:0.15g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010105821 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20233789 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010105847 | NHSA |
| 青海晨菲制药有限公司 | 国药准字H20243854 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010106474 | NHSA |
| 桂林南药股份有限公司 | 国药准字H20233678 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010106725 | NHSA |
| 朗天药业(湖北)有限公司 | 国药准字H20244152 | 15ml:0.15g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002010109592 | NHSA |
| 武汉人福利康药业有限公司 | 国药准字H20244197 | 60ml:0.3g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010181917 | NHSA |
| 中润药业有限公司 | 国药准字H20233372 | 15ml:0.15g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002010181979 | NHSA |
| 山西阳和医药技术有限公司 | 国药准字H20249584 | 15ml:0.15g(按C₁₅H₂₈N₄ O ₄计) | Category B (乙) | XJ05AHP148B002010183547 | NHSA |
| 云南先施药业有限公司 | 国药准字H20258166 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010183585 | NHSA |
| 长春澜江医药科技有限公司 | 国药准字H20253095 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010183864 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20244150 | 60ml∶0.3g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010183916 | NHSA |
| 嘉亨(珠海横琴)医药科技有限公司 | 国药准字H20264902 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010184183 | NHSA |
| 湖北美林药业有限公司 | 国药准字H20249474 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010184564 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20243128 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010201495 | NHSA |
| 江苏吴中医药集团有限公司苏州制药厂 | 国药准字H20243215 | 15ml:0.15g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002010201504 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H20243856 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010202087 | NHSA |
| 扬子江药业集团四川海蓉药业有限公司 | 国药准字H20233617 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010202313 | NHSA |
| 陕西博森生物制药股份集团有限公司 | 国药准字H20249216 | 15ml:0.15g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002010202357 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243586 | 60ml:0.3g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010202662 | NHSA |
| 石药集团中诺药业(石家庄)有限公司 | 国药准字H20243670 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010202777 | NHSA |
| 国药集团容生制药有限公司 | 国药准字H20243671 | 15ml:0.15g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010203205 | NHSA |
| 吉林四环制药有限公司 | 国药准字H20234725 | 20ml:0.2g(以C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010203492 | NHSA |
| 福安药业集团烟台只楚药业有限公司 | 国药准字H20243908 | 20ml∶0.2g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010204251 | NHSA |
| 安徽长江药业有限公司 | 国药准字H20244617 | 20ml∶0.2g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010204451 | NHSA |
| 海南葫芦娃药业集团股份有限公司 | 国药准字H20243230 | 20ml:0.2g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010205789 | NHSA |
| 海南通用三洋药业有限公司 | 国药准字H20243076 | 15ml:0.15g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010205821 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20233789 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010205847 | NHSA |
| 青海晨菲制药有限公司 | 国药准字H20243854 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010206474 | NHSA |
| 桂林南药股份有限公司 | 国药准字H20233678 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010206725 | NHSA |
| 朗天药业(湖北)有限公司 | 国药准字H20244152 | 15ml:0.15g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002010209592 | NHSA |
| 中润药业有限公司 | 国药准字H20233372 | 15ml:0.15g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002010281979 | NHSA |
| 江苏吴中医药集团有限公司苏州制药厂 | 国药准字H20243215 | 15ml:0.15g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002010301504 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H20243856 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010302087 | NHSA |
| 陕西博森生物制药股份集团有限公司 | 国药准字H20249216 | 15ml:0.15g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002010302357 | NHSA |
| 石药集团中诺药业(石家庄)有限公司 | 国药准字H20243670 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010302777 | NHSA |
| 吉林四环制药有限公司 | 国药准字H20234725 | 20ml:0.2g(以C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010303492 | NHSA |
| 安徽长江药业有限公司 | 国药准字H20244617 | 20ml∶0.2g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002010304451 | NHSA |
| 海南通用三洋药业有限公司 | 国药准字H20243076 | 15ml:0.15g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010305821 | NHSA |
| 江苏吴中医药集团有限公司苏州制药厂 | 国药准字H20243215 | 15ml:0.15g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002010401504 | NHSA |
| 吉林四环制药有限公司 | 国药准字H20234725 | 20ml:0.2g(以C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010403492 | NHSA |
| 海南通用三洋药业有限公司 | 国药准字H20243076 | 15ml:0.15g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002010405821 | NHSA |
| 江苏吴中医药集团有限公司苏州制药厂 | 国药准字H20243910 | 60ml∶0.3g(按C15H28N4O4计) | Category B (乙) | XJ05AHP148B002020101504 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243585 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002020102662 | NHSA |
| 国药集团容生制药有限公司 | 国药准字H20243672 | 20ml:0.2g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002020103205 | NHSA |
| 武汉人福利康药业有限公司 | 国药准字H20244196 | 15ml:0.15g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002020181917 | NHSA |
| 云南先施药业有限公司 | 国药准字H20233672 | 20ml∶0.2g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002020181979 | NHSA |
| 山西阳和医药技术有限公司 | 国药准字H20249584 | 15ml:0.15g(按C₁₅H₂₈N₄ O ₄计) | Category B (乙) | XJ05AHP148B002020183547 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243585 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002020202662 | NHSA |
| 国药集团容生制药有限公司 | 国药准字H20243672 | 20ml:0.2g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002020203205 | NHSA |
| 武汉人福利康药业有限公司 | 国药准字H20244196 | 15ml:0.15g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002020281917 | NHSA |
| 云南先施药业有限公司 | 国药准字H20233672 | 20ml∶0.2g(按C₁₅H₂₈N₄O₄ 计) | Category B (乙) | XJ05AHP148B002020281979 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243585 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002020302662 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243585 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002020402662 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243585 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002020502662 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243585 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002020602662 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20243585 | 15ml:0.15g(按C₁₅H₂₈N₄O₄计) | Category B (乙) | XJ05AHP148B002020702662 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 7 filings and 7 distinct first applicants.
Generic 6 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 湖北长联杜勒制药有限公司 | CYHS2602403 | Generic | 2026/09/24 | Not stated by source | CDE |
| 河北天成药业股份有限公司 | CYHB2601809 | Supplement | 2026/09/23 | Not stated by source | CDE |
| 辰欣药业股份有限公司 | CYHS2601554 | Generic | 2026/07/01 | Not stated by source | CDE |
| 开封明仁药业有限公司;辅仁药业集团有限公司 | CYHS2600509 | Generic | 2026/02/25 | Not stated by source | CDE |
| 哈尔滨三联药业股份有限公司 | CYHS2502916 | Generic | 2025/08/12 | Not stated by source | CDE |
| 海南惠普森医药生物技术有限公司 | CYHS2502187 | Generic | 2025/06/18 | Not stated by source | CDE |
| 山东方明药业集团股份有限公司 | CYHS2502112 | Generic | 2025/06/12 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 湖北长联杜勒制药有限公司 | CYHS2602403 | Generic | 2026/09/24 | Not stated by source | CDE |
| 辰欣药业股份有限公司 | CYHS2601554 | Generic | 2026/07/01 | Not stated by source | CDE |
| 开封明仁药业有限公司;辅仁药业集团有限公司 | CYHS2600509 | Generic | 2026/02/25 | Not stated by source | CDE |
API registrations
Non-component matches: 12 companies with A status and 3 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 帕拉米韦 | 湖南先施制药有限公司 | Y20250001299 | I | Exact ingredient | 2025/12/09 | CDE |
| 帕拉米韦 | 重庆朗天制药有限公司 | Y20250001029 | I | Exact ingredient | 2025/10/10 | CDE |
| 帕拉米韦 | 蚌埠丰原涂山制药有限公司 | Y20240001310 | A | Exact ingredient | 2026/08/07 | CDE |
| 帕拉米韦 | 植恩生物技术股份有限公司 | Y20230001127 | A | Exact ingredient | 2026/08/22 | CDE |
| 帕拉米韦 | 汉瑞药业（荆门）有限公司 | Y20220001317 | A | Exact ingredient | 2026/05/06 | CDE |
| 帕拉米韦 | 杭州福斯特药业有限公司 | Y20220000643 | A | Exact ingredient | 2024/04/08 | CDE |
| 帕拉米韦 | 河北天成药业股份有限公司 | Y20220000572 | A | Exact ingredient | 2026/09/22 | CDE |
| 帕拉米韦 | 福安药业集团宁波天衡制药有限公司 | Y20220000324 | A | Exact ingredient | 2025/07/24 | CDE |
| 帕拉米韦 | 重庆博腾制药科技股份有限公司 | Y20220000488 | A | Exact ingredient | 2024/03/25 | CDE |
| 帕拉米韦 | 湖北四环制药有限公司 | Y20210001292 | A | Exact ingredient | 2023/10/09 | CDE |
| 帕拉米韦 | 天津泰普制药有限公司 | Y20210001138 | A | Exact ingredient | 2023/06/07 | CDE |
| 帕拉米韦 | 湖南九典宏阳制药有限公司 | Y20210000127 | A | Exact ingredient | 2025/05/21 | CDE |
| 帕拉米韦 | 苏州正济药业有限公司 | Y20200001197 | A | Exact ingredient | 2024/12/13 | CDE |
| 帕拉米韦 | 湖南凯铂生物药业有限公司 | Y20190009834 | A | Exact ingredient | 2023/03/24 | CDE |
| 帕拉米韦 | 湖南凯铂生物药业有限公司 | Y20190000298 | I | Exact ingredient | 2019/04/29 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/03Marketing application approved
山东益康药业股份有限公司
CYHS2502356 · 国药准字H20266521
Fact date: 2026/11/03 · Publication date: 2026/11/05 · Site observation date: 2026/11/06
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 89 ↗ -
2026/09/24Accepted
-
2026/09/23Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Peramivir Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy